- May 22, 2023Source: Society of Interventional Radiology
The current and future role of artificial intelligence in interventional radiology
- May 06, 2021Source: Healthcare In Europe
The promise and reality about AI for interventional oncology
- April 16, 2019
Interventional Radiologists Perez Lozada and Marino Create First Endovascular Fistula in Connecticut
- March 14, 2019
New Treatment to Remove Clots Offers Dramatic Results
- February 17, 2019
Yale First in Connecticut to Offer Advanced Cardiac Test
Interventional Radiology
General Information
P.O. Box 208042, South Pavilion 2-213
New Haven, CT 06520-8042 |
Phone:
Fax: |
203-785-4747
203-737-1077 |
Yale Interventional Radiology consists of a division of physicians specializing in the use of imaging modalities to guide the performance of minimally invasive diagnostic and therapeutic procedures in numerous parts of the body. Additionally, we are closely allied with Yale Vascular Surgery in a Yale Vascular Center, especially in the evaluation and treatment of arterial and venous blockages and aneurysms, including newer methods for angioplasty, the removal of material causing arterial blockage, and stent-grafts for aneurysms.
Clinical Interests
Other clinical interests include embolization for uterine fibroids, vascular anomalies, and pelvic congestion syndrome and varicoceles; minimally invasive treatment of cancer using embolization (including chemoembolization) and local treatments such as radiofrequency ablation; the management of varicose veins; interventions in bile ducts and the urinary track; and the placement of a variety of venous access devices.
Through the Yale Vascular Malformation Center, we are a world leader in the evaluation and treatment of patients with hereditary hemorrhagic telangiectasia (HHT, or Osler-Weber-Rendu syndrome).
Yale Interventional Radiologists see patients at our office in the Yale Physicians’ Building on Howard Avenue and perform procedures at Yale-New Haven Hospital and at the Veterans Administration Medical Center. In addition, we are active in training residents and fellows and conduct research.
Research Direction
- Outcome of embolotherapy for pulmonary arteriovenous malformations
- Transjugular intrahepatic portosystemic shunts
- Locoregional therapy for hepatocellular carcinoma
- Outcome after uterine fibroid embolization
- Carotid artery stenosis
- Thrombolytic spects and applications
- CT angiography of peripheral vascular disease
- Dynamic vascular imaging
- Clinical applications of phase contrast imaging
- Hemodialysis access catheters
- Endovascular surgery
- Stent technology
- Vascular imaging: improving vascular outcomes
- Fenestrated endografts; branched endografts
- Embolotherapy technics
- Vascular malformations
- Male infertility
- Pelvic congestion syndrome and fibroid disease
- Hereditary Hemorrhagic Telangiectasia
Yale Interventional Oncology Research Lab
Yale IR offers a unique research environment that encompasses the full gamut of basic, translational and clinical science, including clinical trials. Our NIH-funded science focuses on topics such as drug delivery, novel molecular targeted imaging and therapeutics, artificial intelligence and advanced intra-procedural navigation systems. We collaborate with partners in immunobiology, biomedical engineering and biophysics and have the most advanced experimental imaging equipment at our disposal, including a fully equipped state-of-the art Philips Allura Clarity C-Arm Interventional Suite. Our group has a track record of fostering careers of excellent IR trainees and junior faculty. Previous researchers and physician-scientists in IR won numerous national and international research prizes, such as the RSNA Trainee Prize, SIR Constantine Cope award, ECR Invest in Youth award and the prestigious PEO Foundation Award for Excellent Women in Science. Additional information can be found at the Yale Interventional Oncology Research Lab Website.
Education
Yale IR residency training in the Yale New Haven Medical Center program is the only IR training program in the state of Connecticut. Yale IR residency received continued accreditation from the ACGME in 2019. We offer three IR Internship-Residency positions per year. We are accepting IR Intern-Residency applications through ERAS/NRMP on a yearly basis. For more information about the Yale IR residency program, click here.
Yale IR Global Outreach
Yale IR is a leader in global IR, bringing minimally invasive treatment options to underserved populations worldwide. In collaboration with Emory University and Muhimbili University of Health and Allied Sciences, Yale IR has established the first accredited IR training program in sub-Saharan Africa. Before initiation of this training program there was not a single interventional radiologist in Tanzania, an East African nation with a population of nearly 60 million people. This means that many essential and life-saving procedures could not be performed. Yale IR has coordinated deployment of 14 teams to Tanzania for two-week teaching trips since 2018, overseeing more than 300 IR procedures ranging from simple biopsies to complex vascular procedures. Yale IR recognizes the important role minimally invasive treatments will play in improving medical care in Africa and is committed to making these advances available to as many people as possible. This work is supported by several institutional and national grants, including the RSNA Research & Education Foundation Derek Harwood-Nash International Scholar Grant. For more information visit Yale IR Outreach Program Website and @road2IR on Twitter, Facebook, and Instagram.
Recent Publications
2024
- Disorders with Ophthalmic and Thoracic Involvement.Gosangi B, Lang P, Johnson M, Zukerman R, Tu L, Traube L, Bader AS, Rubinowitz AN. Radiographics. 2024 Jul. PMID: 38870047.
- Image-guided percutaneous strategies to improve the resectability of HCC: Portal vein embolization, liver venous deprivation, or radiation lobectomy?Chan SM, Cornman-Homonoff J, Lucatelli P, Madoff DC. Clin Imaging. 2024 Jul; 2024 May 13. PMID: 38781614.
- Brain AVM compactness score in children with hereditary hemorrhagic telangiectasia.Beslow LA, Vossough A, Kim H, Nelson J, Lawton MT, Pollak J, Lin DDM, Ratjen F, Hammill AM, Hetts SW, Gossage JR, Whitehead KJ, Faughnan ME, Krings T. Childs Nerv Syst. 2024 Jul; 2024 Mar 22. PMID: 38517485.
- Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison.Charalel RA, Mushlin AI, Zheng X, Mao J, Carlos R, Brown RS Jr, Ibrahim S, Fortune BE, Talenfeld AD, Madoff DC, Johnson MS, Sedrakyan A. AJR Am J Roentgenol. 2024 Jun 20; 2024 Jun 20. PMID: 38899842.
- Author Correction: Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.Uhlig J, Uhlig A, Deshpande H, Ströbel P, Trojan L, Lotz J, Hurwitz M, Hafez O, Humphrey P, Grünwald V, Kim HS. Sci Rep. 2024 May 24; 2024 May 24. PMID: 38789511.
- Early Liver Cancer Treatments: All Important Options.Charalel RA, Mushlin AI, Mao J, Fortune B, Madoff DC, Johnson MS, Sedrakyan A. J Am Coll Radiol. 2024 May 6; 2024 May 6. PMID: 38719105.
- Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.Uhlig J, Uhlig A, Deshpande H, Ströbel P, Trojan L, Lotz J, Hurwitz M, Hafez O, Humphrey P, Grünwald V, Kim HS. Sci Rep. 2024 May 2; 2024 May 2. PMID: 38693188.
- Recurrence of Pulmonary Arteriovenous Malformation after Embolization in Patients with Pulmonary Hypertension.Fish A, Wang D, Knight E, Pollak J, Schlachter T. J Vasc Interv Radiol. 2024 Apr 29; 2024 Apr 29. PMID: 38692392.
- Understanding Bias in Artificial Intelligence: A Practice Perspective.Davis MA, Wu O, Ikuta I, Jordan JE, Johnson MH, Quigley E. AJNR Am J Neuroradiol. 2024 Apr 8; 2024 Apr 8. PMID: 38123951.
- Bladder-Induced Compression of the External Iliac Veins: Recognition and Implications for Treatment.Cornman-Homonoff J, Deshmukh AP, Perez Lozada JC, Mojibian H. Vasc Endovascular Surg. 2024 Apr; 2023 Nov 14. PMID: 37961845.
- External Disruption of Ocular Development in Utero.Kim HS, Sarrafpour S, Teng CC, Liu J. Yale J Biol Med. 2024 Mar; 2024 Mar 29. PMID: 38559457.
- Multicenter Quantification of Radiation Exposure and Associated Risks for Prostatic Artery Embolization in 1476 Patients.Ayyagari R, Rahman SZ, Grizzard K, Mustafa A, Staib LH, Makkia RS, Bhatia S, Bilhim T, Carnevale FC, Davis C, Fischman A, Isaacson A, McClure T, McWilliams J, Nutting C, Richardson A, Salem R, Sapoval M, Yu H. Radiology. 2024 Mar. PMID: 38441098.
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Lancet. 2024 Feb 17; 2024 Jan 18. PMID: 38246194.
- Effect of Incomplete Cryoablation and Matrix Metalloproteinase Inhibition on Intratumoral CD8(+) T-Cell Infiltration in Murine Hepatocellular Carcinoma.Shewarega A, Santana JG, Nam D, Berz A, Tefera J, Kahl V, Mishra SK, Coman D, Duncan J, Roberts SJ, Wetter A, Madoff DC, Chapiro J. Radiology. 2024 Feb. PMID: 38349244.
- Predictors for Early Liver Cancer Survival After Ablation and Surgical Resection: A Surveillance, Epidemiology, and End Results Program-Medicare Study.Charalel RA, Mushlin AI, Zheng X, Mao J, Carlos R, Brown RS Jr, Fortune BE, Talenfeld AD, Madoff DC, Ibrahim S, Johnson MS, Sedrakyan A. J Am Coll Radiol. 2024 Feb; 2023 Nov 2. PMID: 37922972.